HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome.

AbstractOBJECTIVE:
To systematically review the efficacy of treatment of fibromyalgia syndrome (FMS) with antidepressants.
METHODS:
We screened Medline, PsychINFO, SCOPUS, and the Cochrane Library databases (through October 2007) and the reference sections of original studies, meta-analyses, and evidence-based guidelines and recommendations on antidepressants in FMS. Randomized controlled trials (RCTs) on the treatment of FMS with antidepressants were analyzed. Inclusion criteria, study characteristics, quality, and all outcome measures were investigated.
RESULTS:
Twenty-six of 167 studies were included. The main outcome variables reviewed were pain, fatigue, sleep, depressiveness, and quality of life. Amitriptyline, studied in 13 RCTs, was efficient in reducing pain with a moderate magnitude of benefit (pain reduction by a mean of 26%, improvement in quality of life by 30%). Selective serotonin reuptake inhibitors (SSRIs) were studied in 12 RCTs, which also showed positive results, except for 2 studies on citalopram and 1 on paroxetine. Three RCTs on the dual serotonin and noradrenaline reuptake inhibitors (SNRIs) duloxetine and milnacipran and 1 of the 2 RCTs using the monoamine oxidase inhibitor moclobemide reported a positive result. The longest study duration was 12 weeks.
CONCLUSION:
Amitriptyline 25-50 mg/day reduces pain, fatigue, and depressiveness in patients with FMS and improves sleep and quality of life. Most SSRIs and the SNRIs duloxetine and milnacipran are probably also effective. Short-term treatment of patients with FMS using amitriptyline or another of the antidepressants that were effective in RCTs can be recommended. Data on long-term efficacy are lacking.
AuthorsNurcan Uçeyler, Winfried Häuser, Claudia Sommer
JournalArthritis and rheumatism (Arthritis Rheum) Vol. 59 Issue 9 Pg. 1279-98 (Sep 15 2008) ISSN: 0004-3591 [Print] United States
PMID18759260 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review, Systematic Review)
Chemical References
  • Antidepressive Agents
  • Amitriptyline
Topics
  • Amitriptyline (therapeutic use)
  • Antidepressive Agents (therapeutic use)
  • Databases, Bibliographic
  • Depression (drug therapy, etiology)
  • Fatigue (drug therapy, etiology)
  • Fibromyalgia (drug therapy, physiopathology, psychology)
  • Humans
  • Pain (drug therapy, etiology)
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: